Genetic Treatment Approaches in Rare Pediatric Diseases

References (25)

1. 1 Current Clinical Applications of In Vivo Gene Therapy with AAVs [DOI]
2. 2 Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study [DOI]
3. 3 European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy [DOI]
4. 4 A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders [DOI]
5. 5 Intrathecal Gene Therapy for Giant Axonal Neuropathy [DOI]
6. 6 Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study [DOI]
7. 7 AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient [DOI]
8. 8 Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy [DOI]
9. 9 Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors [DOI]
10. 10 Viral Vectors in Gene Replacement Therapy [DOI]
11. 11 Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study [DOI]
12. 12 Gene therapy for ultrarare diseases: a geneticist’s perspective [DOI]
13. 13 Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec [DOI]
14. 14 Investigating adverse genomic and regulatory changes caused by replacement of the full-length CFTR cDNA using Cas9 and AAV [DOI]
15. 15 Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome [DOI]
16. 16 Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy [DOI]
17. 17 Clinical Characteristics of Charcot-Marie-Tooth Disease Type 4J [DOI]
18. 18 Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective [DOI]
19. 19 Safety concerns surrounding AAV and CRISPR therapies in neuromuscular treatment [DOI]
20. 20 Human HPSE2 gene transfer ameliorates bladder pathophysiology in a mutant mouse model of urofacial syndrome [DOI]
21. 21 Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study [DOI]
22. 22 A comprehensive literature scoping review of infection prevention and control methods for viral-mediated gene therapies [DOI]
23. 23 Adeno-associated virus-mediated gene therapy for rare pediatric neurogenetic diseases: Current status and outlook. [DOI]
24. 24 Gene therapy - once just a dream, now a reality.
25. 25 Optimization of systemic AAV9 gene therapy in Niemann-Pick disease type C1 mice [DOI]

Cited by 0

No indexed citations yet.

Related research

• HIV Disclosure in Children in a Tertiary Hospital in Southern Nigeria–Child’s Perspective — shares topic coverage
• Congenital Melanocytic Hairy Nevi in a Child from North-Western Nigeria — shares topic coverage
• Aflatoxins, Dairy Products Contamination in the Incidence and Development of Diseases in Children Population – A Short Systematic Review — shares topic coverage
• Creating a Disability Variable for Children with Disability Using the WHO ICF-CY Classification System — shares topic coverage
• Knowledge on Child Protection among Children: A Study on Selected Schools in Munali Constituency of Lusaka, Zambia — shares topic coverage